MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - Apr 16, 2013) -
MorphoSys AG Martinsried/Planegg Securities Code Numbers: 663200 and A1RFJ5 ISIN: DE0006632003 and DE000A1RFJ5
Convenience Translation:
The text decisive for the invitation to the Annual General Meeting of MorphoSys AG is the one written in the German language.
Invitation to the Annual General Meeting 2013 of MorphoSys AG
We hereby invite the shareholders of our Company to the Annual General Meeting which is taking place on June 4, 2013 at 10:00 a.m., in the Conference Centre Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.
Agenda
1. Presentation of the adopted financial statements and the approved consolidated financial statements as of December 31, 2012, the management reports including the report of the Supervisory Board for the financial year 2012 and the explanatory report of the Management Board regarding the disclosures pursuant to sec.s 289 para. 4, 315 para. 4 German Commercial Code (HGB)
2. Resolution on the use of the accumulated profit of MorphoSys AG for the financial year 2012
3. Resolution on the formal approval of the activities of the members of the Management Board in respect of the financial year 2012
4. Resolution on the formal approval of the activities of the members of the Supervisory Board in respect of the financial year 2012
5. Resolution on the appointment of the auditor for the financial year 2013
6. Resolution on the amendment of the authorization to issue convertible bonds based on the resolution of the Annual General Meeting on May 14, 2008 and the corresponding provision of the Articles of Association to avoid shares with a deviating entitlement to dividend
7. Resolution on the creation of a new Authorized Capital 2013-I with the possibility to exclude pre-emptive rights of the shareholders; amendment of the Articles of Association
Please find the full text of the invitation here: www.morphosys.com/agm
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com .
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1693039]
For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Loser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 Mario Brkulj Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 Alexandra Goller Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-332 Email Contact
